OTC · PJET
Priority Aviation, Inc.
$0.00$0.00 (0.0%)
Priority Aviation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
Loading market information…
OTC · ATRX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Adhera Therapeutics Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Adhera Therapeutics Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 |
|---|
| May 16, 2022 |
| -$0.60 |
| $0.00 |
| Q1 2022 | Apr 15, 2022 | -$2.20-253.85% vs estimate | $0.00-100.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Priority Aviation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Motus GI Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.8% below the high.
$0.00$0.00 (0.0%)
eFFECTOR Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
Proteonomix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
CannAmerica Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
IMRIS Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.1% below the high.
$0.00$0.00 (0.0%)
GlobeImmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.75% below the high.
